IRIX
Iridex·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IRIX
Iridex Corporation
A worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market
Healthcare Equipment and Supplies
--
02/15/1996
NASDAQ Stock Exchange
93
12-31
Common stock
1212 Terra Bella Avenue
, Mountain View
, CA 94043
--
Iridex Corporation was founded in February 1989 in California as IRIS Medical Instruments Corporation. In November 1995, the company changed its name from Delaware to Iridex Corporation. The Company is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures for the treatment of vision-threatening eye diseases, including glaucoma and retinal diseases.
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS-0.1
Estimate Revenue--
Actual Revenue11.90M
IRIDEX's Q1 2025: Navigating Contradictions in Tariffs, Product Strategy, and Financial Discipline
May 20,2025 10:27
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS--
Actual EPS-0.09
Estimate Revenue--
Actual Revenue12.50M
IRIDEX's Q3 2025 Earnings Call: Contradictions Emerge on Glaucoma and Retina Revenue Growth, Operating Expenses, Cash Flow, and Gross Margins
Nov 11,2025 06:54
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
IRIX has released its 2025 Q3 earnings. EPS was reported at -0.09, versus the expected -0.06, missing expectations. The chart below visualizes how IRIX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IRIX has released its 2025 Q3 earnings report, with revenue of 12.48M, reflecting a YoY change of 7.80%, and net profit of -1.57M, showing a YoY change of 18.62%. The Sankey diagram below clearly presents IRIX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
